Abstract
Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Williams, R. O., Paleolog, E. & Feldmann, M. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr. Opin. Pharmacol. 7, 412–417 (2007).
Shealy, D. et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFα. Ann. Rheum. Dis. 66 (Suppl 2), 151 (2007).
Zhou, H. et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47, 383–2396 (2007).
Food and Drug Administration. FDA labelling information. FDA web site [online] (2009).
Lonberg, N. Fully human antibodies from transgenic mouse and phage display platforms. Curr. Opin. Immunol. 20, 450–459 (2008).
Smolen, J. S. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210–221 (2009).
Keystone, E. C. et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann. Rheum. Dis. 68, 789–796 (2009).
Kavanaugh, A. et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60, 976–986 (2009).
Inman, R. D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58, 3402–3412 (2008).
Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594–1602 (2000).
van der Heijde, D. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54, 1063–1074 (2006).
Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).
Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319–3329 (2008).
Wallis, R. S. Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis. 22, 403–409 (2009).
Kay, J. et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 58, 964–975 (2008).
Visvanathan, S. et al. E-selectin, interleukin 18, serum amyloid A, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J. Rheumatol. 36, 1371–1379 (2009).
IMS MIDAS (2008).
Lewis, D. et al. Morgan Stanley report (Morgan Stanley, April 2009).
Arnold, C. et al. Credit Suisse report (Credit Suisse, July 2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J.M.B. has research contracts with Biogen Idec, Merck Serono and Pfizer, and holds consulting positions at Roche, Crescendo Biosciences and Centocor.
Rights and permissions
About this article
Cite this article
Pappas, D., Bathon, J., Hanicq, D. et al. Golimumab. Nat Rev Drug Discov 8, 695–696 (2009). https://doi.org/10.1038/nrd2982
Issue Date:
DOI: https://doi.org/10.1038/nrd2982
This article is cited by
-
A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis
Clinical Rheumatology (2013)
-
Golimumab and malignancies: true or false association?
Medical Oncology (2011)
-
Fresh from the biologic pipeline—2009
Nature Biotechnology (2010)
-
Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases
Protein & Cell (2010)